Filtered By:
Source: The Journal of Heart and Lung Transplantation
Condition: Bleeding
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 41 results found since Jan 2013.
Managing Anticoagulation in LVAD Patients: The Harefield Experience
Anticoagulation management in patients with Left Ventricular Assist devices (LVAD) continues to be a challenge. Patients and their clinicians are faced with the daily challenge of needing adequate anticoagulation versus the bleeding risks that are associated with anticoagulation.Warfarin is the recommended oral anticoagulant for all currently available LVAD devices.Warfarin is known to be a difficult medication to manage due to its narrow therapeutic window, and its many interactions .Dlott et al (2014) describe in Circulation the overall time in therapeutic range for patients on warfarin as 53.7%, Time in therapeutic rang...
Source: The Journal of Heart and Lung Transplantation - March 25, 2017 Category: Transplant Surgery Authors: R. Hards, G. Edwards, C. Kavanagh, M. Hedger, A.R. Simon Source Type: research
Increased Frequency of Bleeding Complications in Females Following LVAD Implant
While females are at increased risk for stroke after left ventricular assist device (LVAD), the impact of sex on mortality has been met with conflicting results and there is few data on sex specific bleeding rates. Bleeding is a major source of morbidity and mortality in the LVAD population. The aim of this analysis is to define the incidence and clinical impact of bleeding stratified by sex.
Source: The Journal of Heart and Lung Transplantation - March 25, 2017 Category: Transplant Surgery Authors: Z. Yavar, J. Cowger, S. Moainie, C. Salerno, A.K. Ravichandran Source Type: research
Outcomes of Asian-Americans Undergoing Left Ventricular Assist Device Implantations as a Bridge to Transplant or Destination Therapy: An INTERMACS Analysis
Previous studies have demonstrated significant differences between Asians and Caucasian white populations in their propensity for stroke, coronary artery disease, heart failure, inflammation, bleeding and thrombosis. Therefore, we hypothesized that Asian Americans with end stage heart failure undergoing treatment with durable left ventricular assist devices (LVAD) exhibit a different morbidity and mortality risk profile when compared to non-Asian and white Americans populations.
Source: The Journal of Heart and Lung Transplantation - March 25, 2017 Category: Transplant Surgery Authors: J.R. Wever Pinzon, W. Wang, N. Hu, R. Larsen, T. Yu, L. Yin, I. Taleb, A. Koliopoulou, S. Mckellar, J. Stehlik, J. Fang, A. Kfoury, C. Selzman, S. Drakos Source Type: research
CHA2DS2-Vasc and HAS-BLED Scores as Predictors of Ischemic and Hemorrhagic Stroke Risk After Left Ventricular Assist Device Implantation
CHA2DS2-VASc score predicts thromboembolic event risk and HAS-BLED score predicts major bleeding risk in patients on anticoagulation with atrial fibrillation. We aimed to evaluate if these scoring systems would be predictive of ischemic stroke and intracranial bleeding complications following continuous-flow left ventricular assist device (CF-LVAD) implantation.
Source: The Journal of Heart and Lung Transplantation - April 1, 2015 Category: Transplant Surgery Authors: H.S. Kemal, S. Ertugay, S. Nalbantgil, M. Zoghi, C. Engin, T. Yagdi, M. Ozbaran Source Type: research
Temporal Differences in Adverse Event Rates in Patients Bridged With the HeartWare Left Ventricular Assist Device
Left ventricular assist devices (LVAD) have significantly improved survival and quality of life in patients with advanced heart failure. However, these devices are associated with significant adverse events (AEs), particularly bleeding, infection, stroke and right heart failure. We sought to evaluate temporal differences in AE rates in patients bridged to transplantation.
Source: The Journal of Heart and Lung Transplantation - April 1, 2015 Category: Transplant Surgery Authors: S. Maltais, K.D. Aaronson, J.J. Teuteberg, M.S. Slaughter, S.S. Najjar, V. Jeevanandam, D.T. Pham, E.C. McGee, K. Najarian, R.L. Kormos Source Type: research
Temporal Distribution of Hematologic Complications During Berlin EXCOR Support
The Berlin Heart EXCOR trial demonstrated a high incidence of bleeding complications and stroke. Little is known, however, with regards to the timing of these events. The purpose of this study is to describe a single center experience with the Berlin EXCOR VAD, with a particular focus on the temporal distribution of these mutually related complications.
Source: The Journal of Heart and Lung Transplantation - April 1, 2015 Category: Transplant Surgery Authors: S. Burki, D.H. Mahoney, A. Jeewa, W. Zhang, E. McKenzie, D.L. Morales, C.M. Mery, J.S. Heinle, C.D. Fraser, I. Adachi Source Type: research
First Implantation in Man of a New Magnetically Levitated Left Ventricular Assist Device (HeartMate III)
Outcomes of heart failure patients supported by a continuous flow left ventricular assist device (LVAD) have steadily improved over the past decade due in large part to better patient selection and management 1,2. Nevertheless, adverse events such as bleeding, infection, stroke and thrombus persist and limit the overall effectiveness of this therapy. Bleeding is the most common serious adverse event that results from the extensive surgery required for implantation and blood component damage due to shear forces in the small blood flow paths of current design axial-flow and centrifugal-flow pumps.
Source: The Journal of Heart and Lung Transplantation - March 7, 2015 Category: Transplant Surgery Authors: Jan D. Schmitto, Jasmin S. Hanke, Sebastian V. Rojas, Murat Avsar, Axel Haverich Source Type: research
Post-approval study of a highly pulsed, low-shear-rate, continuous-flow, left ventricular assist device, EVAHEART: A Japanese multicenter study using J-MACS
Conclusions: The EVAHEART device provides safe, reliable and long-term circulatory support with improved survival in commercial settings of BTT in Japan, where the transplant waiting period is much longer. Incidences of GI bleeding, hemolysis, right ventricular failure, device thrombosis and mechanical failure were extremely rare in patients on EVAHEART devices.
Source: The Journal of Heart and Lung Transplantation - March 6, 2014 Category: Transplant Surgery Authors: Satoshi Saito, Kenji Yamazaki, Tomohiro Nishinaka, Yuki Ichihara, Minoru Ono, Syunei Kyo, Takashi Nishimura, Takeshi Nakatani, Koichi Toda, Yoshiki Sawa, Ryuji Tominaga, Tadahisa Tanoue, Yoshikatsu Saiki, Yoshiro Matsui, Takahiro Takemura, Hiroshi Niinami Tags: Featured Articles Source Type: research
Association between cell-derived microparticles and adverse events in patients with nonpulsatile left ventricular assist devices
Background: Continuous-flow left ventricular assist devices (LVADs) expose blood cells to high shear stress, potentially resulting in the production of microparticles that express phosphatidylserine (PS+) and promote coagulation and inflammation. In this prospective study, we attempted to determine whether PS+ microparticle levels correlate with clinical outcomes in LVAD-supported patients.Methods: We enrolled 20 patients undergoing implantation of the HeartMate II LVAD (Thoratec Corp, Pleasanton, CA) and 10 healthy controls who provided reference values for the microparticle assays. Plasma was collected before LVAD implan...
Source: The Journal of Heart and Lung Transplantation - January 21, 2014 Category: Transplant Surgery Authors: Angelo Nascimbene, Ruben Hernandez, Joggy K. George, Anita Parker, Angela L. Bergeron, Subhashree Pradhan, K. Vinod Vijayan, Andrew Civitello, Leo Simpson, Maria Nawrot, Vei-Vei Lee, Hari R. Mallidi, Reynolds M. Delgado, Jing Fei Dong, O.H. Frazier Tags: Featured Articles Source Type: research
Low-molecular-weight heparin for anti-coagulation after left ventricular assist device implantation
Conclusions: LMWH in the setting of LVAD shows rapid and constant biologic efficacy. Anti-coagulation with LMWH appears feasible after LVAD implantation. These findings support further evaluation of LMWH as an alternative to unfractionated heparin in this patient cohort.
Source: The Journal of Heart and Lung Transplantation - October 28, 2013 Category: Transplant Surgery Authors: Sigrid E. Sandner, Julia Riebandt, Thomas Haberl, Stephane Mahr, Angela Rajek, Heinrich Schima, George M. Wieselthaler, Guenther Laufer, Daniel Zimpfer Tags: Featured Articles Source Type: research
Gastrointestinal bleeding and subsequent risk of thromboembolic events during support with a left ventricular assist device
Background: Modern left ventricular assist devices (LVAD) require anti-coagulation (AC) with warfarin and anti-platelet therapy to prevent thromboembolic complications in patients. Gastrointestinal bleeding (GI) is a significant adverse event in these patients and treatment typically requires reduction or elimination of AC or anti-platelet therapy. It is not known whether alterations in AC to treat GI bleeding influence subsequent risk of thromboembolic (TE) events during LVAD support.Methods: Between July 2003 and September 2011, 389 patients (308 male) underwent implantation of a continuous-flow LVAD at the University of...
Source: The Journal of Heart and Lung Transplantation - September 9, 2013 Category: Transplant Surgery Authors: John M. Stulak, Dustin Lee, Jonathon W. Haft, Matthew A. Romano, Jennifer A. Cowger, Soon J. Park, Keith D. Aaronson, Francis D. Pagani Tags: Featured Articles Source Type: research
